275 related articles for article (PubMed ID: 36469102)
41. Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations.
Ali H; Puccio I; Akarca AU; Bob R; Pomplun S; Keong Wong W; Gupta R; Sekhar M; Lambert J; Al-Masri H; Stein H; Marafioti T
Int J Exp Pathol; 2021 Feb; 102(1):45-50. PubMed ID: 32929772
[TBL] [Abstract][Full Text] [Related]
42. Molecular genetics of MDS/MPN overlap syndromes.
Hunter AM; Padron E
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101195. PubMed ID: 33038984
[TBL] [Abstract][Full Text] [Related]
43. Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?
Sangiorgio VFI; Orazi A; Arber DA
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101139. PubMed ID: 32460987
[TBL] [Abstract][Full Text] [Related]
44. Clinical, Histopathological and Molecular Spectrum of Cutaneous Lesions in Myelodysplastic Syndrome and Myeloproliferative Neoplasms (MDS/MPN): An Integrative Review.
Prieto-Torres L; Requena L; Rodríguez-Pinilla SM
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136431
[TBL] [Abstract][Full Text] [Related]
45. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
46. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
47. JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome.
Krah NM; Miotke L; Li P; Patel JL; Bowen AR; Pomicter AD; Patel AB
J Natl Compr Canc Netw; 2023 Dec; 21(12):1218-1223. PubMed ID: 38081125
[TBL] [Abstract][Full Text] [Related]
48. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
49. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
50. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Long B; Shi H; Zhu C
Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
[No Abstract] [Full Text] [Related]
51. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
[TBL] [Abstract][Full Text] [Related]
52. Clinical Application for Diagnosis of Myelodysplatic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis.
Lee MY; Jang S; Park CJ; Cho YU
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443589
[TBL] [Abstract][Full Text] [Related]
53. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
54. Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.
Zoi K; Cross NC
Int J Hematol; 2015 Mar; 101(3):229-42. PubMed ID: 25212680
[TBL] [Abstract][Full Text] [Related]
55. Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.
Khan M; Sarfraz M; Daver N
Future Oncol; 2017 Jan; 13(2):117-120. PubMed ID: 27676208
[No Abstract] [Full Text] [Related]
56. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
57. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Mangaonkar AA; Swoboda DM; Lasho TL; Finke C; Ketterling RP; Reichard KK; Komrokji R; Padron E; Patnaik MM
Leuk Res; 2023 Aug; 131():107340. PubMed ID: 37356165
[No Abstract] [Full Text] [Related]
58. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
Gerke MB; Christodoulou I; Karantanos T
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
[TBL] [Abstract][Full Text] [Related]
59. Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
Hochman MJ; Savani BN; Jain T
EJHaem; 2021 Aug; 2(3):607-615. PubMed ID: 35844680
[TBL] [Abstract][Full Text] [Related]
60. Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.
Komrokji R; Melody M; Al Ali N; Chan O; Klimek V; Ball BJ; Sekeres MA; Lucas G; Maciejewski JP; Sallman DA; Padron E; Kuykendall A; Lasho T; Al-Kali A; Naqvi K; Steensma DP; Garcia-Manero G; Patnaik MM
Leuk Lymphoma; 2022 Jan; 63(1):199-204. PubMed ID: 34448437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
